These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23417315)

  • 41. Recurrent high-grade glioma.
    Quant EC; Drappatz J; Wen PY; Norden AD
    Curr Treat Options Neurol; 2010 Jul; 12(4):321-33. PubMed ID: 20842591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
    Korones DN; Smith A; Foreman N; Bouffet E
    Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
    Reardon DA; Herndon JE; Peters K; Desjardins A; Coan A; Lou E; Sumrall A; Turner S; Sathornsumetee S; Rich JN; Boulton S; Lipp ES; Friedman HS; Vredenburgh JJ
    J Neurooncol; 2012 Mar; 107(1):213-21. PubMed ID: 21997879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiangiogenic Therapy of High-Grade Gliomas.
    Jo J; Wen PY
    Prog Neurol Surg; 2018; 31():180-199. PubMed ID: 29393186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
    Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.
    Nagane M; Nishikawa R; Narita Y; Kobayashi H; Takano S; Shinoura N; Aoki T; Sugiyama K; Kuratsu J; Muragaki Y; Sawamura Y; Matsutani M
    Jpn J Clin Oncol; 2012 Oct; 42(10):887-95. PubMed ID: 22844129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ipilimumab and Bevacizumab in Glioblastoma.
    Carter T; Shaw H; Cohn-Brown D; Chester K; Mulholland P
    Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):622-626. PubMed ID: 27169593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bevacizumab as salvage therapy for progressive brain stem gliomas.
    Reithmeier T; Lopez WO; Spehl TS; Nguyen T; Mader I; Nikkhah G; Pinsker MO
    Clin Neurol Neurosurg; 2013 Feb; 115(2):165-9. PubMed ID: 22652237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
    Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
    Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
    Sathornsumetee S; Cao Y; Marcello JE; Herndon JE; McLendon RE; Desjardins A; Friedman HS; Dewhirst MW; Vredenburgh JJ; Rich JN
    J Clin Oncol; 2008 Jan; 26(2):271-8. PubMed ID: 18182667
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiogenic inhibition in high-grade gliomas: past, present and future.
    Jo J; Schiff D; Purow B
    Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
    Ghiaseddin A; Reardon D; Massey W; Mannerino A; Lipp ES; Herndon JE; McSherry F; Desjardins A; Randazzo D; Friedman HS; Peters KB
    Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant intraarterial chemotherapy with nimustine in the management of World Health Organization Grade IV gliomas of the brain. Experience at the Department of Neurosurgery of Düsseldorf University.
    Roosen N; Kiwit JC; Lins E; Schirmer M; Bock WJ
    Cancer; 1989 Nov; 64(10):1984-94. PubMed ID: 2553234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
    Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
    J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
    Kurz SC; Cabrera LP; Hastie D; Huang R; Unadkat P; Rinne M; Nayak L; Lee EQ; Reardon DA; Wen PY
    Neurology; 2018 Oct; 91(14):e1355-e1359. PubMed ID: 30171077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas.
    Yerram P; Reiss SN; Modelevsky L; Gavrilovic IT; Kaley T
    J Neurooncol; 2019 Oct; 145(1):57-63. PubMed ID: 31432377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.
    Hundsberger T; Brügge D; Putora PM; Weder P; Weber J; Plasswilm L
    J Neurooncol; 2013 Mar; 112(1):133-9. PubMed ID: 23314822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.